info:eu-repo/semantics/article
Effects of rapamycin in combination with fludarabine on primary chronic lymphocytic leukemia cells
Fecha
2019-04Registro en:
Rodriguez, Cecilia M.; Bussi, Claudio; Arroyo, Daniela Soledad; Sastre, Dario Ariel; Heller, Viviana; et al.; Effects of rapamycin in combination with fludarabine on primary chronic lymphocytic leukemia cells; Taylor & Francis Ltd; Leukemia and Lymphoma; 60; 5; 4-2019; 1299-1303
1042-8194
1029-2403
CONICET Digital
CONICET
Autor
Rodriguez, Cecilia M.
Bussi, Claudio
Arroyo, Daniela Soledad
Sastre, Dario Ariel
Heller, Viviana
Stanganelli, Carmen Graciela
Slavutsky, Irma Rosa
Iribarren, Pablo
Resumen
Chronic lymphocytic leukemia (CLL) is the most commontype of leukemia in adults, characterized by the expansionof a population of monoclonal CD5þB-lymphocytesthat accumulate in the blood, bone marrow, and secondarylymphoid tissues [1]. CLL continues to be an incurabledisease and can arise in two forms, aggressive and indolent,both characterized by a typical defect in apoptosis.Unfavorable prognosis is associated with the absence ofmutations in the immunoglobulin heavy chain variable(UM-IGHV) genes and by the expression of CD38 andhigh level of 70 kD zeta-associated protein (ZAP-70),among other markers [2,3]. Chromosomal alterations aredetected in >80% of cases and can discriminate patientswith different outcomes [4]. Deletions at chromosome13q14 are the most frequent genomic aberrationdetected by interphase fluorescence in situ hybridization(FISH) analysis. Interestingly, the microRNA miR-15a andmiR-16-1, which target the antiapoptotic molecule Bcl-2,are located in this chromosomal region. [4]. Accordingly,the majority of CLL patients are characterized by aconstitutively elevated expression of Bcl-2, suggestingthat resistance to apoptosis plays an important role inthe disease